Skip to content
Trending
August 4, 2025Here’s where the jobs are in this slowing economy August 5, 2025Shares of American Eagle surge 20% after Trump calls Sydney Sweeney campaign ‘hottest ad out there’ August 4, 2025Fed governors Bowman, Waller explain their dissents, say waiting to cut rates threatens economy August 4, 2025Berkshire Hathaway operating earnings dip 4% as conglomerate braces for tariff impact August 5, 2025Palantir tops $1 billion in revenue for the first time, boosts guidance August 5, 2025Contentious July jobs report confirms the U.S. economy is slowing sharply. Here’s why August 5, 2025Ray Dalio sells his last remaining stake in Bridgewater, steps away from hedge fund’s board
EverydayRead
  • HOME
  • Business
  • Earnings
  • Economy
  • Finance
EverydayRead
EverydayRead
  • HOME
  • Business
  • Earnings
  • Economy
  • Finance
EverydayRead
  Business  FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Business

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

AdminAdmin—July 14, 20250

Watch CNBC's full interview with FDA commissioner Dr. Marty Makary

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday. 

The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are supporting “U.S. national interests.” But previous announcements on the voucher program did not explicitly mention making drugs more affordable as a criterion. 

“We are including the affordability of drugs as a national priority,” Makary told CNBC.

Lowering drug prices is a key goal of the Trump administration, which is facing a tough balancing act as it threatens to impose up to 200% tariffs on pharmaceuticals

Advertisement
imported into the U.S. in a bid to reshore drug manufacturing.

Commissioner of the Food and Drugs Administration Marty Makary speaks at a news conference on removing synthetic dyes from America’s food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025.

Nathan Posner | Anadolu | Getty Images

More stories

How UnitedHealthcare became the face of America’s health insurance frustrations

May 23, 2025

It’s the last chance for Southwest plane tickets with two free checked bags, as policy ends in days

May 27, 2025

NFL will fine more than 100 players for reselling Super Bowl tickets at a profit

July 28, 2025

Darden Restaurants beats earnings estimates, as Olive Garden parent predicts growth in 2026

June 23, 2025

Makary added that President Donald Trump is “very adamant that he would lower drug prices for Americans, and he doesn’t like it that Americans are getting ripped off with drugs that are two, five, 10 times higher” in the U.S. compared to other developed countries.

But it is unclear how the Trump administration will consider affordability when reviewing a drug, as prices for a product’s launch are usually determined after an approval in the U.S.

The FDA’s website currently outlines four examples of “national priorities” that will be used to determine which companies will get a voucher under the new program. That includes addressing a health crisis in the U.S., delivering “more innovative cures” to Americans, addressing unmet public health needs and “increasing domestic drug manufacturing as a national security issue.” 

Drug affordability may have been included previously, according to a Wall Street Journal report in June. 

A spokesperson for the Department of Health and Human Services confirmed that the FDA will consider drug affordability for the program, adding the criteria aren’t limited to earlier examples.

When asked to provide examples of a health crisis that companies can meet with their drugs, Makary said he wants to see a cure for Type 1 diabetes, more treatments for neurodegenerative diseases and a universal flu shot “so we don’t have to try to guess which strain is coming.” 

He also said he wants to see more treatments for stage 4 cancer, or when the disease has spread from its original site to distant parts of the body. 

“We have a committee that’s set up that will determine which products and companies will get these vouchers as part of a pilot,” Makary said. “But we’ve got to try new things. We’ve got to ask ourselves, why does it take so long to come to market? And we want to see more cures and meaningful treatments for Americans.”

The FDA will give out new vouchers this year. After a one-year pilot phase, the agency may increase the number of quick approvals it gives to companies.

Some Wall Street analysts have previously said the voucher program could be more effective than tariffs at encouraging drugmakers to bring their manufacturing to the U.S. 

But questions remain about the risks of speeding up drug reviews to as little as 30 days, which is the fastest the FDA has ever done.

Another potential concern is whether the FDA will offer vouchers to political allies of the Trump administration, which could include companies that agency staff would normally scrutinize. 

Trump budget chief Vought ramps up criticism of Powell, vows investigation into Fed renovations
CrowdStrike drops about 6% on lackluster guidance, ongoing impact from July IT outage
Related posts
  • Related posts
  • More from author
Business

Shares of American Eagle surge 20% after Trump calls Sydney Sweeney campaign ‘hottest ad out there’

August 5, 20250
Business

JFK airport’s $9.5 billion international terminal is taking shape. See what’s inside

August 3, 20250
Business

Why Black entrepreneurs flock to Martha’s Vineyard every August

August 2, 20250
Load more
Read also
Finance

Ray Dalio sells his last remaining stake in Bridgewater, steps away from hedge fund’s board

August 5, 20250
Economy

Contentious July jobs report confirms the U.S. economy is slowing sharply. Here’s why

August 5, 20250
Earnings

Palantir tops $1 billion in revenue for the first time, boosts guidance

August 5, 20250
Business

Shares of American Eagle surge 20% after Trump calls Sydney Sweeney campaign ‘hottest ad out there’

August 5, 20250
Finance

Fed governors Bowman, Waller explain their dissents, say waiting to cut rates threatens economy

August 4, 20250
Economy

Here’s where the jobs are in this slowing economy

August 4, 20250
Load more
© 2023, All Rights Reserved.
  • About Us
  • Advertise With Us
  • Contact Us
  • Disclaimer
  • Cookie Law
  • Privacy Policy
  • Terms & Conditions